NeoLumina

News Blog

Psychedelics in 2024: a year for investment

Psychedelics in 2024: a year for investment

Psychedelics in 2024: a year for investmentFollowing several transformative milestones in psychedelics, coupled with a surge in biotech investment, 2024 is set to see a profound shift for the sector as investors turn their attention toward solutions in mental health....

read more
Psilocybin May Help Some Who Battle Anorexia

Psilocybin May Help Some Who Battle Anorexia

Psilocybin May Help Some Who Battle Anorexia (HealthDay News) -- One dose of the hallucinogenic ingredient in "magic mushrooms" may help some people with anorexia move past their preoccupation with body image, an early study suggests. The study, of just 10 women with...

read more
Psilocybin Shows Early Promise for Anorexia Nervosa

Psilocybin Shows Early Promise for Anorexia Nervosa

Psilocybin Shows Early Promise for Anorexia NervosaThe psychedelic psilocybin may have a role in the treatment of anorexia nervosa (AN), an eating disorder that is notoriously difficult and costly to treat. In a very small phase 1 trial of 10 women with AN, a single...

read more
Mapping the effects of ketamine on the brain

Mapping the effects of ketamine on the brain

Mapping the effects of ketamine on the brainA new study has mapped the effects of ketamine on the brain, finding that repeated use over extended periods creates widespread structural changes in the brain’s dopamine system. The study found that repeated ketamine...

read more
Compass Pathways launches Phase 3 psilocybin trial in UK

Compass Pathways launches Phase 3 psilocybin trial in UK

Compass Pathways launches Phase 3 psilocybin trial in UKCompass Pathways has confirmed that the UK component of its Phase 3 trial investigating psilocybin for treatment-resistant depression has now launched. The trial will be carried out at multiple sites in the UK,...

read more
Psilocin prodrug receives USPTO development approval

Psilocin prodrug receives USPTO development approval

Psilocin prodrug receives USPTO development approvalEnveric Biosciences has received a Notice of Allowance (NoA) from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the company’s new chemical entity (NCE) prodrug of...

read more
Psychedelic research receives Young Investigator Grants

Psychedelic research receives Young Investigator Grants

Psychedelic research receives Young Investigator GrantsThe Brain & Behavior Research Foundation has announced it is awarding $10.2 million in Young Investigator Grants including for projects investigating psychedelics. The grants have been awarded to 150 promising...

read more
New Study Shows Candy-Flipping Can Reduce Bad Trips

New Study Shows Candy-Flipping Can Reduce Bad Trips

New Study Shows Candy-Flipping Can Reduce Bad TripsA new study published in Nature shows that MDMA can reduce difficult experiences with other psychedelics. “Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive...

read more
Otsuka Pharmaceutical agrees to buy Mindset Pharma

Otsuka Pharmaceutical agrees to buy Mindset Pharma

Otsuka Pharmaceutical agrees to buy Mindset PharmaThe acquisition has received approvals from the boards of directors of both companies. Otsuka Pharmaceutical has signed a definitive agreement to acquire drug discovery-based research and development company Mindset...

read more
Psychedelics Research and Psilocybin Therapy

Psychedelics Research and Psilocybin Therapy

Psychedelics Research and Psilocybin Therapy The Johns Hopkins Center for Psychedelic and Consciousness Research is leading the way in exploring innovative treatments using psilocybin. The molecular structure of psilocybin, a naturally occurring psychedelic compound...

read more
Psychedelic Treatment for Eating Disorders

Psychedelic Treatment for Eating Disorders

Psychedelic Treatment for Eating DisordersUnlike most other mental health disorders that can be treated successfully by medication, eating disorders have not been found to be as responsive to traditional psychiatric medicines. Anorexia nervosa has one of the highest...

read more

General Inquiries

Investor Relations